Companies › SKYE
SKYE BIOSCIENCE INC (SKYE)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001516551 · EDGAR filings · Updated 2026-06-23
SKYE BIOSCIENCE INC (SKYE) has reported institutional ownership of 48.3%, with 39 institutional managers holding positions valued at $9.91M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Latest updates
- 2026-06-23 — Current report (8-K) filed
- 2026-05-29 — Current report (8-K) filed
- 2026-05-15 — Current report (8-K) filed
- 2026-05-11 — Quarterly report (10-Q) filed
- 2026-04-28 — Initial insider ownership filed (Form 3)
- 2026-04-16 — ARS filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, SKYE BIOSCIENCE INC has 39 institutional holders and institutional ownership of 48.3%.
Insider activity
Insiders reported 8 transactions (0 buys, 8 sells) across 3 reporting insiders, with a net reported value of −$1.60M.
Data flags from SEC filings
Related companies
ANNOVIS BIO INC (ANVS) · SAFE PRO GROUP INC (SPAI) · OKYO PHARMA LTD (OKYO) · BeyondSpring Inc (BYSI) · Pasithea Therapeutics Corp (KTTA) · Boundless Bio Inc (BOLD)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-23.